Suciu Ilinca, Delp Johannes, Gutbier Simon, Ückert Anna-Katharina, Spreng Anna-Sophie, Eberhard Philipp, Karreman Christiaan, Schreiber Falk, Madjar Katrin, Rahnenführer Jörg, Celardo Ivana, Amelio Ivano, Leist Marcel
In Vitro Toxicology and Biomedicine, Department Inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, 78457 Konstanz, Germany.
Graduate School of Chemical Biology, University of Konstanz, 78457 Konstanz, Germany.
Antioxidants (Basel). 2023 Jan 10;12(1):164. doi: 10.3390/antiox12010164.
Proteasome inhibition is associated with parkinsonian pathology in vivo and degeneration of dopaminergic neurons in vitro. We explored here the metabolome (386 metabolites) and transcriptome (3257 transcripts) regulations of human LUHMES neurons, following exposure to MG-132 [100 nM]. This proteasome inhibitor killed cells within 24 h but did not reduce viability for 12 h. Overall, 206 metabolites were changed in live neurons. The early (3 h) metabolome changes suggested a compromised energy metabolism. For instance, AMP, NADH and lactate were up-regulated, while glycolytic and citric acid cycle intermediates were down-regulated. At later time points, glutathione-related metabolites were up-regulated, most likely by an early oxidative stress response and activation of NRF2/ATF4 target genes. The transcriptome pattern confirmed proteostatic stress (fast up-regulation of proteasome subunits) and also suggested the progressive activation of additional stress response pathways. The early ones (e.g., HIF-1, NF-kB, HSF-1) can be considered a cytoprotective cellular counter-regulation, which maintained cell viability. For instance, a very strong up-regulation of AIFM2 (=FSP1) may have prevented fast ferroptotic death. For most of the initial period, a definite life-death decision was not taken, as neurons could be rescued for at least 10 h after the start of proteasome inhibition. Late responses involved p53 activation and catabolic processes such as a loss of pyrimidine synthesis intermediates. We interpret this as a phase of co-occurrence of protective and maladaptive cellular changes. Altogether, this combined metabolomics-transcriptomics analysis informs on responses triggered in neurons by proteasome dysfunction that may be targeted by novel therapeutic intervention in Parkinson's disease.
蛋白酶体抑制在体内与帕金森病病理相关,在体外与多巴胺能神经元变性相关。我们在此研究了人LUHMES神经元在暴露于MG-132[100 nM]后的代谢组(386种代谢物)和转录组(3257种转录本)调控情况。这种蛋白酶体抑制剂在24小时内杀死细胞,但在12小时内未降低细胞活力。总体而言,活神经元中有206种代谢物发生了变化。早期(3小时)代谢组变化表明能量代谢受损。例如,AMP、NADH和乳酸上调,而糖酵解和柠檬酸循环中间体下调。在后期时间点,与谷胱甘肽相关的代谢物上调,最有可能是由于早期氧化应激反应和NRF2/ATF4靶基因的激活。转录组模式证实了蛋白稳态应激(蛋白酶体亚基快速上调),也表明了其他应激反应途径的逐渐激活。早期的途径(如HIF-1、NF-κB、HSF-1)可被视为一种细胞保护的细胞反调节,维持了细胞活力。例如,AIFM2(=FSP1)的非常强烈上调可能预防了快速铁死亡。在最初的大部分时间里,并没有做出明确的生死决定,因为在蛋白酶体抑制开始后至少10小时内神经元仍可被挽救。后期反应涉及p53激活和分解代谢过程,如嘧啶合成中间体的丧失。我们将此解释为保护性和适应不良性细胞变化同时发生的阶段。总之,这种代谢组学-转录组学联合分析揭示了蛋白酶体功能障碍在神经元中引发的反应,这些反应可能是帕金森病新型治疗干预的靶点。